| Title |
A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination with Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients (DUO-O) |
| Description |
A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination with Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients (DUO-O) study will assess the efficacy and safety of durvalumab and olaparib when added to standard of care (SoC) in patients with newly diagnosed advanced ovarian cancer.The study consists of 2 independent cohorts which are defined by the breast cancer sensitivity gene (BRCA) mutated (BRCAm) status, based on testing of tumour tissue (ie, tBRCAm status) of the patients. |
| Organism |
Homo sapiens |
| Data Type |
Clinical Research data |
| Data Accessibility |
Open-access |
| BioProject |
PRJCA015596 |
| Release Date |
2023-03-22 |
| Submitter |
Rutie Yin (yrtt2013@163.com) |
| Organization |
West China The Second Hospital |
| Submission Date |
2023-03-20 |